Investment Counsel Co. of Nevada Acquires New Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Investment Counsel Co. of Nevada bought a new position in Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 85,020 shares of the company's stock, valued at approximately $1,182,000. Tyra Biosciences makes up approximately 3.0% of Investment Counsel Co. of Nevada's portfolio, making the stock its 8th biggest holding. Investment Counsel Co. of Nevada owned 0.17% of Tyra Biosciences at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of TYRA. The Manufacturers Life Insurance Company bought a new stake in shares of Tyra Biosciences in the third quarter worth approximately $333,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Tyra Biosciences in the third quarter worth about $593,000. State Street Corp grew its stake in shares of Tyra Biosciences by 4.4% during the 3rd quarter. State Street Corp now owns 384,732 shares of the company's stock valued at $9,045,000 after purchasing an additional 16,248 shares during the period. Barclays PLC increased its position in shares of Tyra Biosciences by 200.5% during the 3rd quarter. Barclays PLC now owns 37,625 shares of the company's stock valued at $884,000 after purchasing an additional 25,106 shares during the last quarter. Finally, Franklin Resources Inc. purchased a new stake in shares of Tyra Biosciences during the 3rd quarter valued at about $278,000. 84.14% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TYRA has been the subject of several recent research reports. UBS Group initiated coverage on shares of Tyra Biosciences in a research report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, Wedbush reissued an "outperform" rating and set a $30.00 price target on shares of Tyra Biosciences in a report on Friday, March 28th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Stock Up 3.6 %

NASDAQ TYRA traded up $0.31 during trading hours on Friday, reaching $8.92. The company's stock had a trading volume of 233,876 shares, compared to its average volume of 248,287. Tyra Biosciences, Inc. has a 1 year low of $6.42 and a 1 year high of $29.60. The firm's 50-day moving average price is $10.38 and its 200-day moving average price is $14.81. The company has a market capitalization of $473.56 million, a price-to-earnings ratio of -5.54 and a beta of 1.19.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.05. Equities research analysts anticipate that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Nina S. Kjellson sold 5,401 shares of Tyra Biosciences stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the transaction, the director now owns 443,885 shares in the company, valued at approximately $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 14,219 shares of company stock valued at $218,098 in the last quarter. 15.40% of the stock is currently owned by insiders.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.